These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 18311895)
21. Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis. Myles ME; Neumann DM; Hill JM Adv Drug Deliv Rev; 2005 Dec; 57(14):2063-79. PubMed ID: 16310884 [TBL] [Abstract][Full Text] [Related]
22. Suppression of choroidal neovascularization by vaccination with epitope peptide derived from human VEGF receptor 2 in an animal model. Takahashi H; Ishizaki H; Tahara H; Tamaki Y; Yanagi Y Invest Ophthalmol Vis Sci; 2008 May; 49(5):2143-7. PubMed ID: 18436847 [TBL] [Abstract][Full Text] [Related]
23. Prodrug of epigallocatechin-3-gallate alleviates choroidal neovascularization via down-regulating HIF-1α/VEGF/VEGFR2 pathway and M1 type macrophage/microglia polarization. Xu J; Tu Y; Wang Y; Xu X; Sun X; Xie L; Zhao Q; Guo Y; Gu Y; Du J; Du S; Zhu M; Song E Biomed Pharmacother; 2020 Jan; 121():109606. PubMed ID: 31743875 [TBL] [Abstract][Full Text] [Related]
25. Approaches toward combining photodynamic therapy with pharmaceuticals that alter vascular microenvironment. Busch T Retina; 2009 Jun; 29(6 Suppl):S36-8. PubMed ID: 19553798 [TBL] [Abstract][Full Text] [Related]
26. Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors: 2. Synthesis and characterization of a novel imide-type prodrug for improving oral absorption. Okaniwa M; Imada T; Ohashi T; Miyazaki T; Arita T; Yabuki M; Sumita A; Tsutsumi S; Higashikawa K; Takagi T; Kawamoto T; Inui Y; Yoshida S; Ishikawa T Bioorg Med Chem; 2012 Aug; 20(15):4680-92. PubMed ID: 22763369 [TBL] [Abstract][Full Text] [Related]
27. Species differences in ocular pharmacokinetics and pharmacological activities of regorafenib and pazopanib eye-drops among rats, rabbits and monkeys. Horita S; Watanabe M; Katagiri M; Nakamura H; Haniuda H; Nakazato T; Kagawa Y Pharmacol Res Perspect; 2019 Dec; 7(6):e00545. PubMed ID: 31763044 [TBL] [Abstract][Full Text] [Related]
28. Photoreceptor status after antivascular endothelial growth factor therapy in exudative age-related macular degeneration. Sayanagi K; Sharma S; Kaiser PK Br J Ophthalmol; 2009 May; 93(5):622-6. PubMed ID: 19208677 [TBL] [Abstract][Full Text] [Related]
29. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration. Dadgostar H; Ventura AA; Chung JY; Sharma S; Kaiser PK Ophthalmology; 2009 Sep; 116(9):1740-7. PubMed ID: 19643484 [TBL] [Abstract][Full Text] [Related]
37. [Macular translocation - a therapeutic approach for neovascular macular degeneration in the era of anti-VEGF therapy?]. Ziemssen F; Gelisken F Klin Monbl Augenheilkd; 2009 Jan; 226(1):31-7. PubMed ID: 19173161 [TBL] [Abstract][Full Text] [Related]
38. Structure-based virtual screening of Src kinase inhibitors. Lee K; Kim J; Jeong KW; Lee KW; Lee Y; Song JY; Kim MS; Lee GS; Kim Y Bioorg Med Chem; 2009 Apr; 17(8):3152-61. PubMed ID: 19321350 [TBL] [Abstract][Full Text] [Related]
39. Expression of vasohibin, an antiangiogenic factor, in human choroidal neovascular membranes. Wakusawa R; Abe T; Sato H; Yoshida M; Kunikata H; Sato Y; Nishida K Am J Ophthalmol; 2008 Aug; 146(2):235-243. PubMed ID: 18486097 [TBL] [Abstract][Full Text] [Related]
40. Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis. La DS; Belzile J; Bready JV; Coxon A; DeMelfi T; Doerr N; Estrada J; Flynn JC; Flynn SR; Graceffa RF; Harriman SP; Larrow JF; Long AM; Martin MW; Morrison MJ; Patel VF; Roveto PM; Wang L; Weiss MM; Whittington DA; Teffera Y; Zhao Z; Polverino AJ; Harmange JC J Med Chem; 2008 Mar; 51(6):1695-705. PubMed ID: 18311900 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]